The overarching theme of the 16th annual not-for-profit healthcare track at J.P. Morgan’s 44th Healthcare Conference was the resilience and brilliance of healthcare systems in the face of evolving challenges. Health systems are now better placed to navigate the complex landscape by focusing on their core identities within the community, care quality, technological advancements and operational efficiency.
Over the course of the conference, presenters from across the country shared their strategies and visions for the future of healthcare to over 1,000 attendees representing over 150 peer health systems and investors, emphasizing their commitment to delivering consumer-centric, high-quality care. Read on to discover some of the key themes shaping not-for-profit healthcare in 2026 and beyond.
1. Community Focus & Consumer-Centric Care in the Age of Digital Transformation
A “back to basics” theme resonated throughout the conference, with many presenters emphasizing a renewed focus on putting consumers first. Organizations are re-examining every touchpoint to reduce friction, improve satisfaction, and ensure that patient care and experience remain central to their strategies. Despite regulatory headwinds and the financial complexities of the industry, health systems across the nation remain optimistic about their ability to improve patient experience and provide proactive, accessible, high-quality care. Across the industry, not-for-profit health systems are prioritizing consumer needs by investing in digital platforms, virtual care, and technology that make healthcare more convenient, personalized, and seamless.
2. Primary Care is Back: Investing in the Continuum of Care
Not-for-profit health systems are making significant investments to strengthen the continuum of care, with a particular focus on expanding primary care, urgent care, and outpatient services. Presenters described opening new clinics, urgent care centers, and hospital-at-home programs as core strategic initiatives, as well as integrating behavioral health and specialty services into primary care settings to improve access and care coordination.
Artificial intelligence and technology are being integrated across health systems to improve clinical outcomes, streamline operations, and enhance workforce productivity. Many organizations are moving beyond pilots to enterprise-wide deployment, with a strong focus on digital automation and workflow efficiency. Several health systems reported adopting ambient listening and clinical scribing tools to reduce administrative burden and improve documentation accuracy for clinicians. Automated scribe solutions and voice-enabled technologies are helping providers spend more time with patients and less time on paperwork. Presenters discussed the use of AI for clinical decision support, predictive analytics for patient safety, and digital platforms for patient engagement and operational efficiency.
4. Financial Resiliency & Operating Discipline
Not-for-profit health systems are focused on financial stability and disciplined cost management, responding to reimbursement pressures and economic uncertainty. Many presenters discussed the multi-year strategies underpinning their operational turnaround since the COVID-19 pandemic, including margin improvement initiatives, capital allocation discipline, and cost reduction programs. Presenters emphasized the importance of operational rigor as an ongoing philosophy and the use of data-driven approaches to monitor performance.
5. The New Operating Model
Many health systems discussed the importance of rethinking their operating models to achieve greater integration, efficiency, and consistency across their organizations. Many of the largest presenters spoke about centralizing shared services, adopting unified digital platforms, and developing scalable, repeatable care models. Organizations are also focusing on consolidating departments, standardizing processes, and leveraging data to drive systemwide improvements.
What are the other trends defining the future of not-for-profit healthcare?
Contact your J.P. Morgan representative to find out more.
Related insights
In-Person Conference
Highlights from the J.P. Morgan healthcare conference
Banking
J.P. Morgan’s Public Finance group offers financial solutions to keep some of the world’s most essential services running. Learn more about public finance.
Investment Banking
Providing investment banking solutions, including M&A, capital raising and risk management, for a broad range of corporations, institutions and governments.
This document was prepared exclusively for the benefit and internal use of the J.P. Morgan client to whom it is directly addressed and delivered (including such client’s subsidiaries, the “Company”) in order to assist the Company in evaluating, on a preliminary basis, the feasibility of a possible transaction or transactions and does not carry any right of publication or disclosure, in whole or in part, to any other party. This document is for discussion purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by J.P. Morgan. Neither this document nor any of its contents may be disclosed or used for any other purpose without the prior written consent of J.P. Morgan. Additionally, this presentation may contain content initially generated by AI or other automated technologies.
The information in this document is based upon any management forecasts supplied to us and reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. J.P. Morgan’s opinions and estimates constitute J.P. Morgan’s judgment and should be regarded as indicative, preliminary and for illustrative purposes only. In preparing this document, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or which was provided to us by or on behalf of the Company or which was otherwise reviewed by us. In addition, our analyses are not and do not purport to be appraisals of the assets, stock, or business of the Company or any other entity. J.P. Morgan makes no representations as to the actual value which may be received in connection with a transaction nor the legal, tax or accounting effects of consummating a transaction. Unless expressly contemplated hereby, the information in this document does not take into account the effects of a possible transaction or transactions involving an actual or potential change of control, which may have significant valuation and other effects.
Notwithstanding anything herein to the contrary, the Company and each of its employees, representatives or other agents may disclose to any and all persons, without limitation of any kind, the U.S. federal and state income tax treatment and the U.S. federal and state income tax structure of the transactions contemplated hereby and all materials of any kind (including opinions or other tax analyses) that are provided to the Company relating to such tax treatment and tax structure insofar as such treatment and/or structure relates to a U.S. federal or state income tax strategy provided to the Company by J.P. Morgan. J.P. Morgan's policies on data privacy can be found at http://www.jpmorgan.com/pages/privacy.
J.P. Morgan is a party to the SEC Research Settlement and as such, is generally not permitted to utilize the firm's research capabilities in pitching for investment banking business. All views contained in this presentation are the views of J.P. Morgan’s Investment Bank, not the Research Department. J.P. Morgan’s policies prohibit employees from offering, directly or indirectly, a favorable research rating or specific price target, or offering to change a rating or price target, to a subject company as consideration or inducement for the receipt of business or for compensation. J.P. Morgan also prohibits its research analysts from being compensated for involvement in investment banking transactions except to the extent that such participation is intended to benefit investors.
Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: https://www.jpmorgan.com/global/disclosures/interbank_offered_rates
JPMorgan Chase & Co. and its affiliates do not provide tax advice. Accordingly, any discussion of U.S. tax matters included herein (including any attachments) is not intended or written to be used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone not affiliated with JPMorgan Chase & Co. of any of the matters addressed herein or for the purpose of avoiding U.S. tax-related penalties.
J.P. Morgan is a marketing name for investment businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide. Securities, syndicated loan arranging, financial advisory, lending, derivatives and other investment banking and commercial banking activities are performed by a combination of J.P. Morgan Securities LLC, J.P. Morgan Securities plc, J.P. Morgan SE, JPMorgan Chase Bank, N.A. and the appropriately licensed subsidiaries and affiliates of JPMorgan Chase & Co. worldwide. J.P. Morgan deal team members may be employees of any of the foregoing entities. J.P. Morgan Securities plc is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. J.P. Morgan SE is authorised as a credit institution by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB).
For information on any J.P. Morgan German legal entity see: https://www.jpmorgan.com/country/US/en/disclosures/legal-entity-information#germany.
For information on any other J.P. Morgan legal entity see: https://www.jpmorgan.com/country/GB/EN/disclosures/investment-bank-legal-entity-disclosures.
JPMS LLC intermediates securities transactions effected by its non-U.S. affiliates for or with its U.S. clients when appropriate and in accordance with Rule 15a-6 under the Securities Exchange Act of 1934. Please consult: www.jpmorgan.com/securities-transactions
This document does not constitute a commitment by any J.P. Morgan entity to underwrite, subscribe for or place any securities or to extend or arrange credit or to provide any other services.
Copyright 2026 JPMorgan Chase & Co. All rights reserved.